APA (7th ed.) Citation

Kubeczko, M., Tudrej, P., Tyszkiewicz, T., Krzywon, A., Oczko-Wojcechowska, M., & Jarząb, M. (2024). Figure 3. miRNA expression in patients with progressive disease (group 1) compared with patients with clinical benefit (stable disease + partial response + complete response; group 2). Statistically significant miR expression levels of (A) miR-200b, (B) miR-34a, (C) miR-21, (D) miR-200a and (E) miR-193b. miR, microRNA. Zenodo.

Chicago Style (17th ed.) Citation

Kubeczko, Marcin, Patrycja Tudrej, Tomasz Tyszkiewicz, Aleksandra Krzywon, Malgorzata Oczko-Wojcechowska, and Michał Jarząb. Figure 3. MiRNA Expression in Patients with Progressive Disease (group 1) Compared with Patients with Clinical Benefit (stable Disease + Partial Response + Complete Response; Group 2). Statistically Significant MiR Expression Levels of (A) MiR-200b, (B) MiR-34a, (C) MiR-21, (D) MiR-200a and (E) MiR-193b. MiR, MicroRNA. Zenodo, 2024.

MLA (9th ed.) Citation

Kubeczko, Marcin, et al. Figure 3. MiRNA Expression in Patients with Progressive Disease (group 1) Compared with Patients with Clinical Benefit (stable Disease + Partial Response + Complete Response; Group 2). Statistically Significant MiR Expression Levels of (A) MiR-200b, (B) MiR-34a, (C) MiR-21, (D) MiR-200a and (E) MiR-193b. MiR, MicroRNA. Zenodo, 2024.